General Counsel · Nautilus Biotechnology, Inc. (NAUT)

Matthew Murphy

FY2021 is the first fiscal year CompBrief holds for Matthew Murphy as a named executive officer of Nautilus Biotechnology; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,790,457

Salary $231,096Stock awards $0

3rd of 3 named executive officers at Nautilus Biotechnology by FY2021 total.

3 named officers on file for Nautilus Biotechnology, FY2021

Matthew Murphy’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Nautilus Biotechnology’s whole pay program stands against its peers

  • Nautilus Biotechnology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NAUT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Matthew Murphy’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Matthew Murphy compensation by year

Nautilus Biotechnology Summary Compensation Table · the one fiscal year held
In US dollars, as Nautilus Biotechnology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$231,096
Bonus$0
Stock awards$0
Option awards$2,484,767
Non-equity incentive$74,344
Pension and deferred compensation$0
All other$250
Total$2,790,457

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Nautilus Biotechnology, Inc. DEF 14A filed April 28, 2022, accession 0001808805-22-000041, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Nautilus Biotechnology, Inc. filed document, accession 0001808805-22-000041. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option326,526—$10.10

Per the Outstanding Equity Awards at Fiscal Year-End table in Nautilus Biotechnology, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2021 proxy (filed April 28, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-03-02Grant or award derivative—160,000$0.00160,000
2025-09-04Purchase—20,000$0.6474,140
2025-03-03Grant or award derivative—160,000$0.00160,000

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Nautilus Biotechnology’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Sujal PatelPresident, Chief Executive Officer and Secretary$6,605,335
Parag MallickChief Scientist$3,999,510
Matthew Murphy · this pageGeneral Counsel$2,790,457

The full Nautilus Biotechnology compensation record

free company brief

This page is one person within Nautilus Biotechnology's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Nautilus Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Matthew Murphy's compensation dossier · One-time report. No refunds.